The Portuguese version of the Clinical Global Impression - Schizophrenia Scale: validation study

Abstract

A b s t r a c t Objectives:The Clinical Global Impression -Schizophrenia Scale was designed to assess severity and treatment response in subjects with schizophrenia involved in naturalistic studies and daily clinical practice. The objective of this study is to validate the Portuguese version of the Clinical Global Impression -Schizophrenia Scale in Brazil by assessing its psychometric properties. Method: Cross-sectional validation study of the Portuguese version of the Clinical Global Impression -Schizophrenia Scale, tested in outpatients and inpatients with schizophrenia (DSM-IV, ICD-10) from 6 centers in Brazil. Concurrent validity and sensitivity to change were assessed by comparison with the Positive and Negative Syndrome Scale, which is considered the gold standard tool to evaluate patients with schizophrenia. Interrater reliability was evaluated by intraclass correlation coefficients (ICC) calculated based on the scoring of two concomitant raters. Results: 70 inpatients and 70 outpatients were evaluated. Total Clinical Global Impression -Schizophrenia Scale and Positive and Negative Syndrome Scale scores were highly correlated (r = 0.79; p < 0.01). Positive (r = 0.86), negative (r = 0.79), depressive (r = 0.66) and cognitive (r = 0.75) symptoms subscale scores were also correlated between both scales (p < 0.01). Sensitivity to change was significantly correlated between the Clinical Global Impression -Schizophrenia Scale and Positive and Negative Syndrome Scale (r = 0.73; p < 0.01). Interrater reliability was substantial for positive symptoms and total scores of the Clinical Global Impression -Schizophrenia Scale (ICC = 0.81 and 0.73), and moderate for negative, depressive, and cognitive symptoms score (0.64, 0.67 and 0.63, respectively). Conclusions: The Brazilian version of the Clinical Global Impression -Schizophrenia Scale is a valid and reliable instrument for the assessment of severity and treatment response in schizophrenic inpatient and outpatients.Descriptors: Schizophrenia; Psychiatric status rating scales; Validity of tests; Validation studies; Multicenter study Resumo Objetivos: A Escala de Impressão Clínica Global -Esquizofrenia é um instrumento de aplicação simples e rápido, utilizado para avaliar a severidade de sintomas em pacientes com esquizofrenia. Pode ser aplicado em estudos naturalísticos e na prática clínica. O objetivo deste trabalho é estudar as propriedades psicométricas e validar a versão Brasileira da Escala de Impressão Clínica Global -Esquizofrenia em nosso meio. Método: Estudo transversal de validação da Escala de Impressão Clínica GlobalEsquizofrenia, na versão em Português, em pacientes com esquizofrenia, hospitalizados e em tratamento ambulatorial (DSM-IV, ICD-10), selecionados em seis centros no Brasil. Validade concorrente e sensibilidade à mudança foram determinadas em comparação com a escala Positive and Negative Syndrome Scale, considerada padrão-ouro. Confiabilidade interavaliador foi determinada através de coeficientes de correlação intraclasse (ICC), calculados a p...

Hair cortisol in drug-naïve first-episode individuals with psychosis

“…All of these instruments have been translated and validated for Brazilian Portuguese. [16][17][18][19][20] Hair cortisol analysis…”

Serum levels of IL-6, IL-10 and TNF-&#945; in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance

“…27 The psychiatric status of patients with SZ was assessed using the Brief Psychiatric Rating Scale (BPRS) 28 and the Clinical Global Impression (CGI). 29 Only patients with BPRS scores ≤ 25 and no history of a psychiatric hospitalization over the last two years were included in the study. Mood symptoms in patients with BD were identified using the Young Mania Rating Scale (YMRS) 30 and the Hamilton Depression Rating Scale (HAMD-21).…”

Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study

“…The current analysis on the longerterm outcomes shows that the increasing probability of patients becoming minimally symptomatic over the first 12 months of treatment continued, but was less pronounced, over the next 24 months. After 36 months of treatment, olanzapine and risperidone was associated with greater weight gain than haloperidol, but the differences were not statistically significant (30), partly because of the low power at 3-year comparison because of discontinuations. A greater proportion of patients remained on therapy with the atypical antipsychotics compared with the typical antipsychotic, haloperidol.…”

“…Patients were permitted to use concomitant medications such as anticholinergics, antidepressants, anxiolytics and mood stabilisers, as clinically indicated. Patients attended eight outpatient visits: at baseline, and at 3,6,12,18,24,30 and 36 months. Patients were included in this treatment group analysis for as long as they remained on the originally prescribed monotherapy during the 36 months of treatment, i.e.…”